| The histone methyltransferase KMT2D maintains cellular glucocorticoid responsiveness by shielding the glucocorticoid receptor from degradation. | The histone methyltransferase KMT2D maintains cellular glucocorticoid responsiveness by shielding the glucocorticoid receptor from degradation.
Wu CJ, Livak F, Ashwell JD., Free PMC Article | 10/23/2024 |
| Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma. | Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma.
Liu W, Cao H, Wang J, Elmusrati A, Han B, Chen W, Zhou P, Li X, Keysar S, Jimeno A, Wang CY., Free PMC Article | 09/17/2024 |
| PI 3-Kinase and the Histone Methyl-Transferase KMT2D Collaborate to Induce Arp2/3-Dependent Migration of Mammary Epithelial Cells. | PI 3-Kinase and the Histone Methyl-Transferase KMT2D Collaborate to Induce Arp2/3-Dependent Migration of Mammary Epithelial Cells.
Rysenkova KD, Gaboriaud J, Fokin AI, Toubiana R, Bense A, Mirdass C, Jin M, Ho MCN, Glading E, Vacher S, Courtois L, Bièche I, Gautreau AM., Free PMC Article | 09/6/2024 |
| Lysine Methyltransferase 2D Regulates Immune Response and Metastasis in Head and Neck Cancer. | Lysine Methyltransferase 2D Regulates Immune Response and Metastasis in Head and Neck Cancer.
Wu J, Chun C, Lagunas AM, Crowe DL. | 07/31/2024 |
| DNA methylation profiling in Kabuki syndrome: reclassification of germline KMT2D VUS and sensitivity in validating postzygotic mosaicism. | DNA methylation profiling in Kabuki syndrome: reclassification of germline KMT2D VUS and sensitivity in validating postzygotic mosaicism.
Niceta M, Ciolfi A, Ferilli M, Pedace L, Cappelletti C, Nardini C, Hildonen M, Chiriatti L, Miele E, Dentici ML, Gnazzo M, Cesario C, Pisaneschi E, Baban A, Novelli A, Maitz S, Selicorni A, Squeo GM, Merla G, Dallapiccola B, Tumer Z, Digilio MC, Priolo M, Tartaglia M., | 07/25/2024 |
| Macular dystrophy in Kabuki syndrome due to de novo KMT2D variants: refining the phenotype with multimodal imaging and follow-up over 10 years: insight into pathophysiology. | Macular dystrophy in Kabuki syndrome due to de novo KMT2D variants: refining the phenotype with multimodal imaging and follow-up over 10 years: insight into pathophysiology.
Vaclavik V, Navarro A, Jacot-Guillarmod A, Bottani A, Sun YJ, Franco JA, Mahajan VB, Smirnov V, Bouvet-Drumare I., Free PMC Article | 05/28/2024 |
| [Clinical and genetic characteristics of four children with Kabuki syndrome due to de novo variants of KMT2D gene]. | [Clinical and genetic characteristics of four children with Kabuki syndrome due to de novo variants of KMT2D gene].
Fan H, Wang Y, Wu Y, Jia L, Wang L, Shen Y. | 05/1/2024 |
| KMT2D Deficiency Causes Sensorineural Hearing Loss in Mice and Humans. | KMT2D Deficiency Causes Sensorineural Hearing Loss in Mice and Humans.
Kalinousky AJ, Luperchio TR, Schrode KM, Harris JR, Zhang L, DeLeon VB, Fahrner JA, Lauer AM, Bjornsson HT., Free PMC Article | 01/31/2024 |
| Hearing characteristics and otoradiological abnormalities in three patients with novel pathogenic variants of KMT2D-related Kabuki syndrome. | Hearing characteristics and otoradiological abnormalities in three patients with novel pathogenic variants of KMT2D-related Kabuki syndrome.
Zheng Z, Ding L, Wang M, Zhang Y, Yang Y, Tang M, Xu J, Wang L, Wu J, Li H., Free PMC Article | 01/31/2024 |
| EBF2 Links KMT2D-Mediated H3K4me1 to Suppress Pancreatic Cancer Progression via Upregulating KLLN. | EBF2 Links KMT2D-Mediated H3K4me1 to Suppress Pancreatic Cancer Progression via Upregulating KLLN.
Yao B, Xing M, Meng S, Li S, Zhou J, Zhang M, Yang C, Qu S, Jin Y, Yuan H, Zen K, Ma C., Free PMC Article | 01/27/2024 |
| SETting up the genome: KMT2D and KDM6A genomic function in the Kabuki syndrome craniofacial developmental disorder. | SETting up the genome: KMT2D and KDM6A genomic function in the Kabuki syndrome craniofacial developmental disorder.
Shpargel KB, Quickstad G., Free PMC Article | 12/20/2023 |
| Molecular insights of KMT2D and clinical aspects of Kabuki syndrome type 1. | Molecular insights of KMT2D and clinical aspects of Kabuki syndrome type 1.
Golden CS, Williams S, Serrano MA., Free PMC Article | 12/1/2023 |
| [Two novel and de novo KMT2D mutations on the same allele cause Kabuki syndrome]. | [Two novel and de novo KMT2D mutations on the same allele cause Kabuki syndrome].
Wu ZY, Yue HT, Li J, Yang JG, Bian Z, He M. | 10/10/2023 |
| Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer. | Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer.
Liu R, Niu Y, Liu C, Zhang X, Zhang J, Shi M, Zou W, Gu B, Zhu H, Wang D, Yuan H, Li W, Zhao D, Zheng Q, Liu R, Chen W, Ma T, Zhang Y., Free PMC Article | 08/11/2023 |
| KMT2D Deficiency Promotes Myeloid Leukemias which Is Vulnerable to Ribosome Biogenesis Inhibition. | KMT2D Deficiency Promotes Myeloid Leukemias which Is Vulnerable to Ribosome Biogenesis Inhibition.
Xu J, Zhong A, Zhang S, Chen M, Zhang L, Hang X, Zheng J, Wu B, Deng X, Pan X, Wang Z, Qi L, Shi K, Li S, Wang Y, Wang M, Chen X, Zhang Q, Liu P, Gale RP, Chen C, Liu Y, Niu T., Free PMC Article | 07/17/2023 |
| MLL4 Regulates the Progression of Non-Small-Cell Lung Cancer by Regulating the PI3K/AKT/SOX2 Axis. | MLL4 Regulates the Progression of Non-Small-Cell Lung Cancer by Regulating the PI3K/AKT/SOX2 Axis.
Yang Y, Qiu R, Weng Q, Xu Z, Song J, Zhao S, Meng M, Zhang D, Kong C, Wang H, Xu M, Zhao Z, Ji J., Free PMC Article | 07/17/2023 |
| The KDM6A-KMT2D-p300 axis regulates susceptibility to diverse coronaviruses by mediating viral receptor expression. | The KDM6A-KMT2D-p300 axis regulates susceptibility to diverse coronaviruses by mediating viral receptor expression.
Wei J, Alfajaro MM, Cai WL, Graziano VR, Strine MS, Filler RB, Biering SB, Sarnik SA, Patel S, Menasche BL, Compton SR, Konermann S, Hsu PD, Orchard RC, Yan Q, Wilen CB., Free PMC Article | 07/12/2023 |
| Characterizing the molecular impact of KMT2D variants on the epigenetic and transcriptional landscapes in Kabuki syndrome. | Characterizing the molecular impact of KMT2D variants on the epigenetic and transcriptional landscapes in Kabuki syndrome.
Jung YL, Hung C, Choi J, Lee EA, Bodamer O. | 06/23/2023 |
| KMT2D links TGF-beta signaling to noncanonical activin pathway and regulates pancreatic cancer cell plasticity. | KMT2D links TGF-β signaling to noncanonical activin pathway and regulates pancreatic cancer cell plasticity.
Lu S, Kim HS, Cao Y, Bedi K, Zhao L, Narayanan IV, Magnuson B, Gu Y, Yang J, Yi Z, Babaniamansour S, Shameon S, Xu C, Paulsen MT, Qiu P, Jeyarajan S, Ljungman M, Thomas D, Dou Y, Crawford H, di Magliano MP, Ge K, Yang B, Shi J., Free PMC Article | 06/21/2023 |
| Histone methyltransferase KMT2D promotes prostate cancer progression through paracrine IL-6 signaling. | Histone methyltransferase KMT2D promotes prostate cancer progression through paracrine IL-6 signaling.
Zhang J, Ye Y, Xu Z, Luo M, Wu C, Zhang Y, Lv S, Wei Q. | 04/4/2023 |
| KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells. | KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells.
Vlasevska S, Garcia-Ibanez L, Duval R, Holmes AB, Jahan R, Cai B, Kim A, Mo T, Basso K, Soni RK, Bhagat G, Dalla-Favera R, Pasqualucci L., Free PMC Article | 03/16/2023 |
| Pan-Cancer Analysis of Histone Methyltransferase KMT2D with Potential Implications for Prognosis and Immunotherapy in Human Cancer. | Pan-Cancer Analysis of Histone Methyltransferase KMT2D with Potential Implications for Prognosis and Immunotherapy in Human Cancer.
Chen G, Chen P, Zhou J, Luo G. | 03/9/2023 |
| Prenatal Phenotype of Kabuki Syndrome: Seven Case Series. | Prenatal Phenotype of Kabuki Syndrome: Seven Case Series.
Zhang L, Li YL, Zhen L, Li R, Li DZ. | 02/14/2023 |
| KMT2D Regulates the NCOA6/THRB Signal Axis through Epigenetic Modification to Promote the Migration and Invasion of Papillary Thyroid Cancer. | KMT2D Regulates the NCOA6/THRB Signal Axis through Epigenetic Modification to Promote the Migration and Invasion of Papillary Thyroid Cancer.
Wang R, He Y, Wang Y, Xie S. | 02/4/2023 |
| Mutational Landscape of Bladder Cancer in Mexican Patients: KMT2D Mutations and chr11q15.5 Amplifications Are Associated with Muscle Invasion. | Mutational Landscape of Bladder Cancer in Mexican Patients: KMT2D Mutations and chr11q15.5 Amplifications Are Associated with Muscle Invasion.
Pérez-Montiel MD, Cerrato-Izaguirre D, Sánchez-Pérez Y, Diaz-Chavez J, Cortés-González CC, Rubio JA, Jiménez-Ríos MA, Herrera LA, Scavuzzo A, Meneses-García A, Hernández-Martínez R, Vaca-Paniagua F, Ramírez A, Orozco A, Cantú-de-León D, Prada D., Free PMC Article | 01/28/2023 |